A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

被引：0
|
作者：
Mantzaris, G. [1 ]
Bressler, B. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Colby, C. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Yarur, A. [12 ]
机构：
[1] Evangelismos Med Ctr, Dept Gastroenterol, Athens, Greece
[2] St Pauls Hosp, Dept Gastroenterol, Vancouver, BC, Canada
[3] Sheba Med Ctr, Dept Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Real World Evidence, San Francisco, CA USA
[6] Takeda Pharmaceut USA Inc, Dept Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Dept Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA Athens, Dept Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Dept Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] Med Coll Wisconsin, Dept Gastroenterol, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP55
引用
收藏
页码：S092 / S094
页数：3
相关论文
共 50 条
  • [21] A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease
    Manuel Navas-Lopez, Victor
    Pujol Muncunill, Gemma
    Llerena, Enrique
    Naval Rubio, Maria
    Gil-Ortega, David
    Varea-Calderon, Vicente
    Sierra Salinas, Carlos
    Martin-de-Carpi, Javier
    ANALES DE PEDIATRIA, 2018, 88 (02): : 89 - 99
  • [22] Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1470 - I1471
  • [23] REAL-WORLD MULTICENTER COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
    Buisson, Anthony
    Nachury, Maria
    Fumery, Mathurin
    Guilmoteau, Thomas
    Leclerc, Eloise
    Altwegg, Romain
    Serrero, Melanie
    Mathieu, Nicolas
    Treton, Xavier
    Vuitton, Lucine
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2022, 162 (07) : S604 - S604
  • [24] Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
    Buisson, A.
    Nachury, M.
    Fumery, M.
    Guilmoteau, T.
    Leclerc, E.
    Altwegg, R.
    Serrero, M.
    Mathieu, N.
    Treton, X.
    Vuitton, L.
    Pereira, B.
    Amiot, A.
    Bouguen, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I120
  • [25] Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzek, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 872 - 872
  • [26] Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study
    Barberio, Brigida
    Zingone, Fabiana
    Frazzoni, Leonardo
    D'Inca, Renata
    Maccarone, Maria Chiara
    Ghisa, Matteo
    Massimi, Davide
    Lorenzon, Greta
    Savarino, Edoardo Vincenzo
    DIGESTIVE DISEASES, 2021, 39 (01) : 16 - 24
  • [27] Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
    Barberio, B.
    Zingone, F.
    D'Inca, R.
    Marinelli, C.
    Maccarone, M. C.
    Gubbiotti, A.
    Cingolani, L.
    Lorenzon, G.
    Ghisa, M.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S548 - S549
  • [28] REAL-WORLD COMPARISON OF LONG-TERM DRUG SURVIVAL OF FIRST-LINE BIOLOGIC AGENTS FOR ULCERATIVE COLITIS
    Dalal, Rahul S.
    McClure, Emma L.
    Marcus, Jenna
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2022, 162 (07) : S605 - S606
  • [29] Adalimumab as first-line anti-TNF treatment in ulcerative colitis. A "real-life" observational study
    Lorente, R.
    Verdejo, C.
    Roncero, O.
    Lopez, D.
    Robledo, P.
    Bouhmidi, A.
    Hervias, D.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S280 - S280
  • [30] Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study
    Komel Pimenta, Pedro Ricardo
    Ribeiro da Silva, Michael Ruberson
    Ribeiro dos Santos, Jessica Barreto
    Kakehasi, Adriana Maria
    Assis Acurcio, Francisco de
    Alvares-Teodoro, Juliana
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 509 - 517
12345